PT-141
A melanocortin receptor agonist (primarily MC3R/MC4R). Research investigates central nervous system pathways related to sexual arousal and function, distinct from vascular-based mechanisms.
Unit Price
Sign in to view pricing.
Purchase requires a verified researcher account and a signed RUO attestation.
All batch test results and certificates of analysis are published below — including any batches that failed testing. Full transparency is our standard.
Mechanism of Action
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. It acts as a non-selective melanocortin receptor agonist, with primary research interest at MC3R and MC4R in the hypothalamus. Unlike PDE5 inhibitors acting on vascular smooth muscle, its mechanism operates through CNS pathways. FDA-approved in 2019 (Vyleesi) for hypoactive sexual desire disorder in premenopausal women; dual mechanism involves nitric oxide release and central arousal modulation.
Research References
Full research page →Rosen RC et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PMID: 14999221
Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019
Simon JA et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. PMID: 31599840
Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003
Related Products
Batch History & Certificates of Analysis
Full Batch Record
No batch records available for this product yet.
For Research Use Only. This product is supplied exclusively for in vitro research, laboratory study, and experimental purposes. It is not a drug, supplement, food, or cosmetic, and is not intended for human or veterinary use. See our Compliance & RUO Policy.